Do analysts recommend BCAB or IMRN?

BioAtla presently has a consensus price target of $200.00, suggesting a potential upside of 15,284.62%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioAtla is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BCAB or IMRN?

Immuron has lower revenue, but higher earnings than BioAtla. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAtla $8.50M 0.25 -$59.61M -$25.45 N/A Immuron $5.47M 1.52 -$2.50M N/A N/A

Is BCAB or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% Immuron N/A N/A N/A

Does the media prefer BCAB or IMRN?

In the previous week, Immuron had 5 more articles in the media than BioAtla. MarketBeat recorded 6 mentions for Immuron and 1 mentions for BioAtla. Immuron's average media sentiment score of 0.71 beat BioAtla's score of 0.00 indicating that Immuron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuron 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCAB or APRE more profitable?

BioAtla's return on equity of 0.00% beat Aprea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% Aprea Therapeutics N/A -47.60% -40.97%

Does the media favor BCAB or APRE?

In the previous week, Aprea Therapeutics had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for Aprea Therapeutics and 1 mentions for BioAtla. Aprea Therapeutics' average media sentiment score of 0.93 beat BioAtla's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCAB or FBLG more profitable?

BioAtla's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% FibroBiologics N/A -536.78% -225.12%

Does the media prefer BCAB or FBLG?

In the previous week, FibroBiologics had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for BioAtla. FibroBiologics' average media sentiment score of 0.46 beat BioAtla's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCAB or OSRH?

BioAtla presently has a consensus target price of $200.00, indicating a potential upside of 15,284.62%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioAtla is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BCAB or OSRH?

OSR has lower revenue, but higher earnings than BioAtla. OSR is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAtla $8.50M 0.25 -$59.61M -$25.45 N/A OSR $1.81M 3.89 -$27.06M -$0.37 N/A

Is BCAB or OSRH more profitable?

BioAtla has a net margin of 0.00% compared to OSR's net margin of -593.15%. BioAtla's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% OSR -593.15% -8.36% -6.24%

Does the media prefer BCAB or OSRH?

In the previous week, OSR had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for OSR and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OSR 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BCAB or NRSN more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% NeuroSense Therapeutics N/A N/A N/A

Does the media refer more to BCAB or NRSN?

In the previous week, NeuroSense Therapeutics had 4 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for NeuroSense Therapeutics and 1 mentions for BioAtla. NeuroSense Therapeutics' average media sentiment score of 0.43 beat BioAtla's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroSense Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioAtla (BCAB) Competitors

$1.30 +0.02 (+1.56%)

As of 10/14/2026 03:56 PM Eastern

Compare

BCAB vs. IMRN, APRE, FBLG, OSRH, and NRSN

Should you buy BioAtla stock or one of its competitors? BioAtla's main competitors and comparable companies include Immuron (IMRN), Aprea Therapeutics (APRE), FibroBiologics (FBLG), OSR (OSRH), and NeuroSense Therapeutics (NRSN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioAtla compare to Immuron?

BioAtla (NASDAQ:BCAB) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Immuron has lower revenue, but higher earnings than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.25	-$59.61M	-$25.45	N/A
Immuron	$5.47M	1.52	-$2.50M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
Immuron	N/A	N/A	N/A

In the previous week, Immuron had 5 more articles in the media than BioAtla. MarketBeat recorded 6 mentions for Immuron and 1 mentions for BioAtla. Immuron's average media sentiment score of 0.71 beat BioAtla's score of 0.00 indicating that Immuron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAtla	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuron	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAtla presently has a consensus price target of $200.00, suggesting a potential upside of 15,284.62%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioAtla is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioAtla has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Immuron has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Summary

BioAtla and Immuron tied by winning 6 of the 12 factors compared between the two stocks.

How does BioAtla compare to Aprea Therapeutics?

BioAtla (NASDAQ:BCAB) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

In the previous week, Aprea Therapeutics had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for Aprea Therapeutics and 1 mentions for BioAtla. Aprea Therapeutics' average media sentiment score of 0.93 beat BioAtla's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAtla	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAtla's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
Aprea Therapeutics	N/A	-47.60%	-40.97%

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioAtla has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 15,284.62%. Aprea Therapeutics has a consensus target price of $2.80, suggesting a potential upside of 380.27%. Given BioAtla's higher probable upside, equities analysts plainly believe BioAtla is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Aprea Therapeutics has lower revenue, but higher earnings than BioAtla. Aprea Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.25	-$59.61M	-$25.45	N/A
Aprea Therapeutics	$290K	25.31	-$12.60M	-$1.08	N/A

Summary

Aprea Therapeutics beats BioAtla on 10 of the 14 factors compared between the two stocks.

How does BioAtla compare to FibroBiologics?

BioAtla (NASDAQ:BCAB) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 15,284.62%. FibroBiologics has a consensus target price of $73.00, suggesting a potential upside of 7,584.21%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts plainly believe BioAtla is more favorable than FibroBiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

FibroBiologics has lower revenue, but higher earnings than BioAtla. FibroBiologics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.25	-$59.61M	-$25.45	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

BioAtla has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market.

In the previous week, FibroBiologics had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for BioAtla. FibroBiologics' average media sentiment score of 0.46 beat BioAtla's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAtla	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.2% of BioAtla shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 7.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioAtla's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
FibroBiologics	N/A	-536.78%	-225.12%

Summary

BioAtla and FibroBiologics tied by winning 6 of the 12 factors compared between the two stocks.

How does BioAtla compare to OSR?

BioAtla (NASDAQ:BCAB) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

BioAtla has a net margin of 0.00% compared to OSR's net margin of -593.15%. BioAtla's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
OSR	-593.15%	-8.36%	-6.24%

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 36.9% of OSR shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioAtla presently has a consensus target price of $200.00, indicating a potential upside of 15,284.62%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioAtla is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OSR has lower revenue, but higher earnings than BioAtla. OSR is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.25	-$59.61M	-$25.45	N/A
OSR	$1.81M	3.89	-$27.06M	-$0.37	N/A

In the previous week, OSR had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for OSR and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAtla	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OSR	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioAtla has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, OSR has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Summary

BioAtla beats OSR on 9 of the 15 factors compared between the two stocks.

How does BioAtla compare to NeuroSense Therapeutics?

BioAtla (NASDAQ:BCAB) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, NeuroSense Therapeutics had 4 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for NeuroSense Therapeutics and 1 mentions for BioAtla. NeuroSense Therapeutics' average media sentiment score of 0.43 beat BioAtla's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAtla	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroSense Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioAtla presently has a consensus price target of $200.00, suggesting a potential upside of 15,284.62%. NeuroSense Therapeutics has a consensus price target of $170.00, suggesting a potential upside of 5,455.56%. Given BioAtla's higher probable upside, research analysts clearly believe BioAtla is more favorable than NeuroSense Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroSense Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

NeuroSense Therapeutics has lower revenue, but higher earnings than BioAtla. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.25	-$59.61M	-$25.45	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
NeuroSense Therapeutics	N/A	N/A	N/A

BioAtla has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

77.2% of BioAtla shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

NeuroSense Therapeutics beats BioAtla on 9 of the 13 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.17M	$3.84B	$7.18B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	-0.05	10.48	216.61	19.63
Price / Sales	0.25	1,147.33	565.61	77.64
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	-0.05	16.17	10.37	5.92
Net Income	-$59.61M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-16.13%	-5.84%	-3.51%	-3.90%
1 Month Performance	-5.11%	-12.90%	-7.78%	-6.42%
1 Year Performance	-96.87%	3.16%	0.86%	-6.01%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	1.0259 of 5 stars	$1.30 +1.6%	$200.00 +15,284.6%	-96.8%	$2.17M	$8.50M	N/A	60	Gap Down
IMRN Immuron	0.5558 of 5 stars	$1.07 flat	N/A	-49.8%	$8.64M	$5.47M	N/A	7	Short Interest Decrease
APRE Aprea Therapeutics	3.8871 of 5 stars	$0.66 -2.9%	$3.07 +367.5%	-61.4%	$8.25M	N/A	N/A	8	News Coverage Analyst Forecast
FBLG FibroBiologics	2.4589 of 5 stars	$1.20 +1.7%	$73.00 +5,983.3%	-88.7%	$7.99M	N/A	N/A	15	News Coverage
OSRH OSR	0.0829 of 5 stars	$0.22 -8.6%	N/A	-63.4%	$7.73M	$1.81M	N/A	N/A	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. IMRN, APRE, FBLG, OSRH, and NRSN

How does BioAtla compare to Immuron?

Summary

How does BioAtla compare to Aprea Therapeutics?

Summary

How does BioAtla compare to FibroBiologics?

Summary

How does BioAtla compare to OSR?

Summary

How does BioAtla compare to NeuroSense Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. IMRN, APRE, FBLG, OSRH, and NRSN

How does BioAtla compare to Immuron?

Which has better earnings & valuation, BCAB or IMRN?

Is BCAB or IMRN more profitable?

Does the media prefer BCAB or IMRN?

Do analysts recommend BCAB or IMRN?

Do insiders and institutionals hold more shares of BCAB or IMRN?

Which has more risk & volatility, BCAB or IMRN?

Summary

How does BioAtla compare to Aprea Therapeutics?

Does the media favor BCAB or APRE?

Is BCAB or APRE more profitable?

Do institutionals & insiders hold more shares of BCAB or APRE?

Which has more risk and volatility, BCAB or APRE?

Do analysts recommend BCAB or APRE?

Which has preferable earnings & valuation, BCAB or APRE?

Summary

How does BioAtla compare to FibroBiologics?

Do analysts rate BCAB or FBLG?

Which has higher earnings and valuation, BCAB or FBLG?

Which has more risk & volatility, BCAB or FBLG?

Does the media prefer BCAB or FBLG?

Do insiders & institutionals hold more shares of BCAB or FBLG?

Is BCAB or FBLG more profitable?

Summary

How does BioAtla compare to OSR?

Is BCAB or OSRH more profitable?

Do institutionals and insiders have more ownership in BCAB or OSRH?

Do analysts rate BCAB or OSRH?

Which has preferable earnings & valuation, BCAB or OSRH?

Does the media prefer BCAB or OSRH?

Which has more risk and volatility, BCAB or OSRH?

Summary

How does BioAtla compare to NeuroSense Therapeutics?

Does the media refer more to BCAB or NRSN?

Do analysts prefer BCAB or NRSN?

Which has higher earnings & valuation, BCAB or NRSN?

Is BCAB or NRSN more profitable?

Which has more volatility and risk, BCAB or NRSN?

Do institutionals and insiders have more ownership in BCAB or NRSN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools